Peters P, Rabbolini D, Sinnya S, Khosrotehrani K, Wagner G. Multiple squamous cell carcinomas following introduction of nilotinib.
Clin Exp Dermatol 2014;
39:791-4. [PMID:
25155911 DOI:
10.1111/ced.12388]
[Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/03/2014] [Indexed: 11/29/2022]
Abstract
BACKGROUND
Nilotinib is a second generation tyrosine kinase inhibitor, used in the treatment of chronic myelogenous leukaemia (CML).
METHODS
We assessed a 72-year-old woman who was treated with nilotinib for CML.
RESULTS
During the year following commencement of nilotinib, the patient developed eight squamous cell carcinomas (SCCs) on her legs.
CONCLUSIONS
Development of SCC is a previously unreported adverse reaction to nilotinib.
Collapse